dossier thématique
Voies excrétrices
urinaires supérieures
L’auteur déclare ne pas avoir
de liens d’intérêts.
Correspondances en Onco-Urologie - Vol. IV - n° 2 - avril-mai-juin 2013
5252
en pT3a pour une infi ltration microscopique du paren-
chyme rénal (< 5 mm) et en pT3b pour une infi ltration
macroscopique du parenchyme rénal ou de la graisse
sinusale. C. Langner et al. ont montré que les patients
souff rant de cancers pT3a et pT3b ont des pronostics
similaires à ceux des patients souff rant de cancers pT2
et pT4, respectivement (39). Une corrélation entre le
stade et le grade a été démontrée, chacune de ces
caractéristiques évoluant dans le même sens.
Conclusion
Les TVEUS sont des cancers rares dont les facteurs
de risque sont très similaires à ceux des tumeurs de
la vessie. Les types histologiques sont aussi à rap-
procher des lésions vésicales. Il ne faut pas négliger
leur histoire naturelle, en raison des variations dues à
diff érents facteurs, notamment la localisation tumo-
rale.
■
1. Rouprêt M, Zigeuner R, Palou J et al. European guidelines for
the diagnosis and management of upper urinary tract urothe-
lial cell carcinomas: 2011 update. Eur Urol 2011;59(4):584-94.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.
CA Cancer J Clin 2012;62(1):10-29.
3.
Siegel R, DeSantis C, Virgo K et al. Cancer treatment and
survivorship statistics, 2012. CA Cancer J Clin 2012;62(4):220-41.
4. Shariat SF, Godoy G, Lotan Y et al. Advanced patient age is
associated with inferior cancer-specifi c survival after radical
nephroureterectomy. BJU Int 2010;105(12):1672-7.
5.
Lughezzani G, Sun M, Perrotte P et al. Gender-related dif-
ferences in patients with stage I to III upper tract urothelial
carcinoma: results from the Surveillance, Epidemiology, and
End Results database. Urology 2010;75(2):321-7.
6. Rink M, Xylinas E, Margulis V et al. Impact of smoking on
oncologic outcomes of upper tract urothelial carcinoma after
radical nephroureterectomy. Eur Urol 2013;63(6):1082-90.
7.
Lord GM, Tagore R, Cook T et al. Nephropathy caused by
Chinese herbs in the UK. Lancet 1999;354(9177):481-2.
8. Colin P, Koenig P, Ouzzane A et al. Environmental factors
involved in carcinogenesis of urothelial cell carcinomas of the
upper urinary tract. BJU Int 2009;104(10):1436-40.
9.
Debelle FD, Vanherweghem JL, Nortier JL. Aristolochic acid
nephropathy: a worldwide problem. Kidney Int 2008;74(2):158-69.
10. Markovic N, Ignjatovic I, Cukuranovic R et al. Decreasing
incidence of urothelial cancer in a Balkan endemic nephro-
pathy region in Serbia. A surgery based study from 1969 to
1998. Pathol Biol (Paris) 2005;53(1):26-9.
11.
Grollman AP, Jelaković B. Role of environmental toxins in
endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia.
J Am Soc Nephrol 2007;18(11):2817-23.
12. Colin P, Koenig P, Ouzzane A et al. Environmental factors
involved in carcinogenesis of urothelial cell carcinomas of the
upper urinary tract. BJU Int 2009;104(10):1436-40.
13.
Tan LB, Chen KT, Guo HR. Clinical and epidemiological fea-
tures of patients with genitourinary tract tumour in a blackfoot
disease endemic area of Taiwan. BJU Int 2008;102(1):48-54.
14. McCredie M, Stewart JH, Ford JM et al. Phenacetin-
containing analgesics and cancer of the bladder or renal
pelvis in women. Br J Urol 1983;55(2):220-4.
15. McCredie M, Stewart JH, Day NE. Diff erent roles for phe-
nacetin and paracetamol in cancer of the kidney and renal
pelvis. Int J Cancer 1993;53(2):245-9.
16. Crockett DG, Wagner DG, Holmäng S et al. Upper uri-
nary tract carcinoma in Lynch syndrome cases. J Urol 2011;
185(5):1627-30.
17. Rouprêt M, Yates DR, Comperat E et al. Upper urinary tract
urothelial cell carcinomas and other urological malignan-
cies involved in the hereditary nonpolyposis colorectal cancer
(Lynch syndrome) tumor spectrum. Eur Urol 2008;54(6):1226-36.
18. Audenet F, Colin P, Yates DR et al. A proportion of hereditary
upper urinary tract urothelial carcinomas are misclassifi ed as
sporadic according to a multi-institutional database analysis:
proposal of patient-specifi c risk identifi cation tool. BJU Int
2012;110(11 Pt B):E583-9.
19. Yates DR, Catto JW. Distinct patterns and behaviour of
urothelial carcinoma with respect to anatomical location:
how molecular biomarkers can augment clinico-patholo-
gical predictors in upper urinary tract tumours. World J Urol
2013;31(1):21-9.
20.
Catto JW, Hartmann A, Stoehr R et al. Multifocal urothelial
cancers with the mutator phenotype are of monoclonal origin
and require panurothelial treatment for tumor clearance. J Urol
2006;175(6):2323-30.
21. Catto JW, Yates DR, Rehman I et al. Behavior of urothe-
lial carcinoma with respect to anatomical location. J Urol
2007;177(5):1715-20.
22. Van Oers JM, Zwarthoff EC, Rehman I et al. FGFR3 muta-
tions indicate better survival in invasive upper urinary tract
and bladder tumours. Eur Urol 2009;55(3):650-7.
23. Hafner C, Knuechel R, Zanardo L et al. Evidence for oligo-
clonality and tumor spread by intraluminal seeding in multi-
focal urothelial carcinomas of the upper and lower urinary
tract. Oncogene 2001;20(35):4910-5.
24.
Hafner C, Knuechel R, Stoehr R et al. Clonality of multifocal
urothelial carcinomas: 10 years of molecular genetic studies.
Int J Cancer 2002;101(1):1-6.
25. Rouprêt M, Azzouzi AR, Cussenot O. Microsatellite instability
and transitional cell carcinoma of the upper urinary tract. BJU
Int 2005;96(4):489-92.
26.
Rouprêt M, Fromont G, Azzouzi AR et al. Microsatellite
instability as predictor of survival in patients with invasive
upper urinary tract transitional cell carcinoma. Urology 2005;
65(6):1233-7.
27.
Hafner C, Knuechel R, Stoehr R et al. Clonality of multifocal
urothelial carcinomas: 10 years of molecular genetic studies.
Int J Cancer 2002;101(1):1-6.
28. Novara G, De Marco V, Dalpiaz O et al. Independent pre-
dictors of metachronous bladder transitional cell carcinoma
(TCC) after nephroureterectomy for TCC of the upper urinary
tract. BJU Int 2008;101(11):1368-74.
29. Xylinas E, Rink M, Margulis V et al. Multifocal carcinoma
in situ of the upper tract is associated with high risk of bladder
cancer recurrence. Eur Urol 2012;61(5):1069-70.
30. Zigeuner RE, Hutterer G, Chromecki T et al. Bladder
tumour development after urothelial carcinoma of the upper
urinary tract is related to primary tumour location. BJU Int
2006;98(6):1181-6.
31.
Azémar MD, Comperat E, Richard F et al. Bladder recur-
rence after surgery for upper urinary tract urothelial cell car-
cinoma: frequency, risk factors, and surveillance. Urol Oncol
2011;29(2):130-6.
32.
Sanderson KM, Rouprêt M. Upper urinary tract tumour
after radical cystectomy for transitional cell carcinoma of the
bladder: an update on the risk factors, surveillance regimens
and treatments. BJU Int 2007;100(1):11-6.
33.
Kikuchi E, Margulis V, Karakiewicz PI et al. Lymphovascular
invasion predicts clinical outcomes in patients with node-
negative upper tract urothelial carcinoma. J Clin Oncol
2009;27(4):612-8.
34. Lughezzani G, Burger M, Margulis V et al. Prognostic factors
in upper urinary tract urothelial carcinomas: a comprehensive
review of the current literature. Eur Urol 2012;62(1):100-14.
35. Lughezzani G, Jeldres C, Isbarn H et al. A critical appraisal of
the value of lymph node dissection at nephroureterectomy for
upper tract urothelial carcinoma. Urology 2010;75(1):118-24.
36. Olgac S, Mazumdar M, Dalbagni G et al. Urothelial carci-
noma of the renal pelvis: a clinicopathologic study of 130 cases.
Am J Surg Pathol 2004;28(12):1545-52.
37. Perez-Montiel D, Wakely PE, Hes O et al. High-grade uro-
thelial carcinoma of the renal pelvis: clinicopathologic study
of 108 cases with emphasis on unusual morphologic variants.
Mod Pathol 2006;19(4):494-503.
38. Sobin L, Gospodarowicz M, Wittekind C. TNM classifi cation
of malignant tumours. Urological tumours. Renal pelvis and
ureter. 7th revised edition. Wiley-Blackwell, uicc 2009:258-61.
39.
Shariat SF, Zigeuner R, Rink M et al. Subclassifi cation of
pT3 urothelial carcinoma of the renal pelvicalyceal system is
associated with recurrence-free and cancer-specifi c survival:
proposal for a revision of the current TNM classifi cation. Eur
Urol 2012;62(2):224-31.
Références